Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Change in Accured Expenses (2024 - 2025)

Connect Biopharma Holdings' Change in Accured Expenses history spans 2 years, with the latest figure at $999000.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 1318.29% year-over-year to $999000.0; the TTM value through Sep 2025 reached $114000.0, changed N/A, while the annual FY2024 figure was -$1.7 million, 72.41% up from the prior year.
  • Change in Accured Expenses for Q3 2025 was $999000.0 at Connect Biopharma Holdings, up from $695000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $999000.0 in Q3 2025 and bottomed at -$1.3 million in Q2 2024.